1 November 2016 in Transplantation Proceedings
1 January 2015 in Ağrı - The Journal of The Turkish Society of Algology
Transforaminal anterior steroid injections are frequently used for low back pain. In the current study, It was aimed to investigate the effects of transforaminal anterior epidural steroid injection (TAESI) in patients with low back pain in regards to quality of life and sleep, and neuropathic pain. Ethics committee approval and patient consent were obtained. Patients with low back pain scheduled to receive transforaminal epidural steroid injections between October 2011 and October 2012 were included into the study. Pittsburgh Sleep Quality Index (PSQI), Short form 12 (SF 12), DN4 tests and Visual Analog Scale Score (VAS) were measured prior to procedure and three months later. All the tests were compared with baseline evaluations prior to injections. One hundred and two (female/male: 52/50) patients with a mean age of 53.3 ± 1.4 were included. Primary diagnoses were lumbar disc herniation in eighty-seven patients, spinal stenosis in seven and failed back surgery syndrome in eight patients. Statistically significant improvement was seen in the total VAS, DN4 and PSQI scores (p=0.0001) of the patients at the third month follow-up. Sleep duration (p=0.0001), habitual sleep efficiency (p=0.0001), subjective sleep quality (p=0.003), sleep latency (p=0.014), sleep disturbances (p<0.001), sleep medication use (p=0.003), and day time dysfunction (p=0.015) showed a significant decrease in sub-components. There was no significant difference in SF 12 quality of life. It was determined in the study that transforaminal epidural steroid injection provided a substantial improvement in patients' pain and neuropathic pain and quality of sleep, but had no effect on the quality of life.
1 February 2023 in Experimental and Clinical Transplantation
Objectives: The most frequent postoperative morbidity following living donor liver transplant is biliary complications, which can happen for both anatomical and procedural reasons. Materials and Methods: We conducted a retrospective analysis of 104 patients who were living liver donors undergoing hepatectomy from January 2011 to April 2022. We evaluated all perioperative finding such as age, sex, remnant liver volume, biliary anatomy, the duration of operation time and hospitalization, and blood loss. Results: Clavien-Dindo classification grade III complications were observed in 24% of all donors, with rate of biliary complications of 7.6% (n = 8). All biliary complications were typified as biliary leakage, and an endoscopic retrograde cholangiopancreatography procedure was performed for 5 patients. We analyzed the clinical and surgical features and discovered that the duration of hospitalization was longer in the biliary leakage group than the group without leakage (15.7 +/- 5.8 days vs. 30.8 +/- 9.3 days, respectively; P < .08). There was no significant statistical relationship between age, the duration of operation time, intraoperative blood loss, and remnant liver volume versus biliary leakage (P = .074, P = .217, P = .219, and P = .363, respectively). Conclusions: Early detection and treatment of complications are ensured during the perioperative process by careful donor selection and accurate identification of the patient at risk for biliary complications.
22 January 2022 in European Journal of Obstetrics & Gynecology and Reproductive Biology
1 May 2021 in İstanbul Kanuni Sultan Süleyman Tıp dergisi
1 February 2025 in Experimental and Clinical Transplantation
MÇMuhammet Kadri Çolakoğlu
+4
Hepatocellular carcinoma is a common type of primary liver cancer and a major cause of cancer-related deaths worldwide. Liver transplantation is the choice of treatment for patients with hepatocellular carcinoma within the Milan criteria. Extrahepatic metastasis is a particularly concerning complication of hepatocellular carcinoma recurrence after liver transplant, associated with poor prognosis, and has limited treatment options. We analyzed our results in the incidence and management of extrahepatic metastasis in patients transplanted for hepatocellular carcinoma. Between 1999 and 2022, 61 patients underwent liver transplant for hepatocellular carcinoma at our center and were included in the study. At our outpatient department, patients who underwent liver transplant for hepatocellular carcinoma had follow-up and tumor surveillance examinations at specific intervals posttransplant. Examinations included physical examination, ultrasonography of the abdomen and liver, radiographic examination of the chest, serum laboratory tests with α-fetoprotein, and ultrasonography-guided liver biopsy. The 61 patients followed up for hepatocellular carcinoma were between 22 and 65 years old; 8 (14.1%) were women. Chronic hepatitis B infection was observed in 36 patients (59%). Extrahepatic metastases were observed in 13 patients during follow-up. The mean recurrence time in the 13 patients who developed extrahepatic hepatocellular carcinoma recurrence was 21 months posttransplant. Extrahepatic recurrence included lung, bone, and spleen metastasis in 7 patients, isolated lung metastasis in 3 patients, seeding metastasis in 2 patients, and isolated bone metastasis in 1 patient. Twenty of the 58 patients included in the study received local ablative therapy before transplant. Hepatocellular carcinoma beyond Milan criteria and microvascular invasion are risk factors for extrahepatic hepatocellular carcinoma recurrence; a multimodal approach is used to manage recurrent disease.